Hormonal
Once-weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle intervention significantly reduces body weight in adults with obesity or overweight.
If you have obesity or overweight with related health issues, ask your doctor about once-weekly semaglutide injections (2.4 mg). It works by suppressing appetite and slowing digestion, leading to significant weight loss (around 15% in trials) when combined with diet and exercise. Be aware of potential stomach issues like nausea, which often improve over time.
Among obese adults, subcutaneous Semaglutide (2.4 mg) given once weekly promotes weight loss via appetite and hunger suppression, decreases energy intake, controls eating, and depresses the relative fondness for fatty, energy-dense foods.
Why this rating
Based on multiple Phase III randomized, double-blind, placebo-controlled clinical trials.
Source
Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
Nasser M. Alorfi et al. · Clinical Pharmacology Advances and Applications · 2022
DOI 10.2147/cpaa.s374741
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →